Futility stopping in clinical trials, optimality and practical considerations

被引：9

作者：

Chang, Yen ^{[1
]}

Song, Tianhao ^{[1
]}

Monaco, Jane ^{[1
]}

Ivanova, Anastasia ^{[1
]}

机构：

[1] Univ N Carolina, Dept Biostat, Chapel Hill, NC 27599 USA

来源：

JOURNAL OF BIOPHARMACEUTICAL STATISTICS | 2020年 / 30卷 / 06期

关键词：

Simon's design; phase; 2; trial; futility stopping; crossover trial; ADMISSIBLE 2-STAGE DESIGNS; EXPECTED SAMPLE-SIZE;

D O I：

10.1080/10543406.2020.1818253

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Stopping for futility is a useful tool in a clinical trial. It is widely used in single-arm trials in oncology and in many two-arm trials. We review three stopping rules for futility. We give recommendations for the optimal timing of futility looks in two-stage trials in terms of the information fraction and the probability of stopping under the alternative hypothesis. We discuss futility stopping in trials with substantial uncertainty about the variability of the outcome and in crossover trials.

引用

页码：1050 / 1059

页数：10

共 18 条

[1] [Anonymous], 1999, GROUP SEQUENTIAL MET
[2] Chen TT, 1997, STAT MED, V16, P2701, DOI 10.1002/(SICI)1097-0258(19971215)16:23<2701::AID-SIM704>3.0.CO
[3] 2-1
[4] DESIGNS FOR GROUP SEQUENTIAL-TESTS
FLEMING, TR
HARRINGTON, DP
OBRIEN, PC
[J]. CONTROLLED CLINICAL TRIALS, 1984, 5 (04): : 348 - 361
[5] He P, 2012, STAT INTERFACE, V5, P415
[6] Alertness and psychomotor performance effects of the histamine-3 inverse agonist MK-0249 in obstructive sleep apnea patients on continuous positive airway pressure therapy with excessive daytime sleepiness: a randomized adaptive crossover study
Herring, W. Joseph
Liu, Kenneth
Hutzelmann, Jill
Snavely, Duane
Snyder, Ellen
Ceesay, Paulette
Lines, Christopher
Michelson, David
Roth, Thomas
[J]. SLEEP MEDICINE, 2013, 14 (10) : 955 - 963
[7] Nine-year change in statistical design, profile, and success rates of Phase II oncology trials
Ivanova, Anastasia
Paul, Barry
Marchenko, Olga
Song, Guochen
Patel, Neerali
Moschos, Stergios J.
[J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2016, 26 (01) : 141 - 149
[8] An adaptive design for identifying the dose with the best efficacy/tolerability profile with application to a crossover dose-finding study
Ivanova, Anastasia
Liu, Ken
Snyder, Ellen
Snavely, Duane
[J]. STATISTICS IN MEDICINE, 2009, 28 (24) : 2941 - 2951
[9] Admissible two-stage designs for phase II cancer clinical trials
Jung, SH
Lee, T
Kim, K
George, SL
[J]. STATISTICS IN MEDICINE, 2004, 23 (04) : 561 - 569
[10] Lan KG., 1982, Sequent Anal, V1, P207

← 1 2 →